| Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy CH Ries, MA Cannarile, S Hoves, J Benz, K Wartha, V Runza, ... Cancer cell 25 (6), 846-859, 2014 | 1311 | 2014 |
| Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1–positive cervical cancer: results from the phase Ib KEYNOTE-028 trial JS Frenel, C Le Tourneau, B O’Neil, PA Ott, SA Piha-Paul, C Gomez-Roca, ... Journal of Clinical Oncology 35 (36), 4035-4041, 2017 | 455 | 2017 |
| Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study C Berthon, E Raffoux, X Thomas, N Vey, C Gomez-Roca, K Yee, ... The Lancet Haematology 3 (4), e186-e195, 2016 | 442 | 2016 |
| Clinical response of carcinomas harboring the BRD4–NUT oncoprotein to the targeted bromodomain inhibitor OTX015/MK-8628 A Stathis, E Zucca, M Bekradda, C Gomez-Roca, JP Delord, ... Cancer discovery 6 (5), 492-500, 2016 | 376 | 2016 |
| CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study PA Cassier, A Italiano, CA Gomez-Roca, C Le Tourneau, M Toulmonde, ... The Lancet Oncology 16 (8), 949-956, 2015 | 354 | 2015 |
| Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1 … PA Ascierto, I Melero, S Bhatia, P Bono, RE Sanborn, EJ Lipson, ... Journal of Clinical Oncology 35 (15_suppl), 9520-9520, 2017 | 269 | 2017 |
| Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal PA Ott, SA Piha-Paul, P Munster, MJ Pishvaian, EMJ Van Brummelen, ... Annals of Oncology 28 (5), 1036-1041, 2017 | 266 | 2017 |
| Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma BH O’Neil, JM Wallmark, D Lorente, E Elez, J Raimbourg, C Gomez-Roca, ... PloS one 12 (12), e0189848, 2017 | 263 | 2017 |
| Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma JP Delord, C Robert, M Nyakas, GA McArthur, R Kudchakar, A Mahipal, ... Clinical Cancer Research 23 (18), 5339-5348, 2017 | 183 | 2017 |
| Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials C Ferté, M Fernandez, A Hollebecque, S Koscielny, A Levy, C Massard, ... Clinical Cancer Research 20 (1), 246-252, 2014 | 180 | 2014 |
| Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior … PA Ascierto, P Bono, S Bhatia, I Melero, MS Nyakas, IM Svane, J Larkin, ... Annals of Oncology 28, v611-v612, 2017 | 171 | 2017 |
| Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities S Postel-Vinay, C Gomez-Roca, LR Molife, B Anghan, A Levy, I Judson, ... J Clin Oncol 29 (13), 1728-1735, 2011 | 145 | 2011 |
| Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like … CA Gomez-Roca, A Italiano, C Le Tourneau, PA Cassier, M Toulmonde, ... Annals of Oncology 30 (8), 1381-1392, 2019 | 144 | 2019 |
| Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites C Gomez-Roca, CM Raynaud, F Penault-Llorca, O Mercier, F Commo, ... Journal of Thoracic Oncology 4 (10), 1212-1220, 2009 | 112 | 2009 |
| Regorafenib-avelumab combination in patients with microsatellite stable colorectal cancer (REGOMUNE): a single-arm, open-label, phase II trial S Cousin, C Cantarel, JP Guegan, C Gomez-Roca, JP Metges, A Adenis, ... Clinical Cancer Research 27 (8), 2139-2147, 2021 | 104 | 2021 |
| Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination A Aboudaram, A Modesto, L Chaltiel, C Gomez-Roca, S Boulinguez, ... Melanoma research 27 (5), 485-491, 2017 | 98 | 2017 |
| Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor … LG Paz-Ares, C Gomez-Roca, JP Delord, A Cervantes, B Markman, ... Journal of clinical oncology 29 (28), 3783-3790, 2011 | 98 | 2011 |
| Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia N Vey, J Delaunay, G Martinelli, W Fiedler, E Raffoux, T Prebet, ... Oncotarget 7 (22), 32532, 2016 | 96 | 2016 |
| Tumour growth rates and RECIST criteria in early drug development C Gomez-Roca, S Koscielny, V Ribrag, C Dromain, I Marzouk, F Bidault, ... European journal of cancer 47 (17), 2512-2516, 2011 | 96 | 2011 |
| First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors CW Menke-van der Houven, C Gomez-Roca, C van Herpen, AL Coveler, ... Oncotarget 7 (48), 80046, 2016 | 88 | 2016 |
